Silence Therapeutics PLC Grant of Options (7819K)
06 January 2021 - 10:08PM
UK Regulatory
TIDMSLN
RNS Number : 7819K
Silence Therapeutics PLC
06 January 2021
Grant of Options
January 6, 2021
LONDON, Silence Therapeutics plc, AIM:SLN and NASDAQ: SLN
("Silence" or "the Company") a leader in the discovery, development
and delivery of novel short interfering ribonucleic acid (siRNA)
therapeutics for the treatment of diseases with significant unmet
medical need, today announced that it has granted 580,000 options
to Craig Tooman, Chief Financial Officer, under the Silence
Therapeutics plc 2018 Employee Long Term Incentive Plan.
Under the grant, 145,000 options will vest on the 12-month
anniversary of the award. A further 36,250 share options will vest
at the end of each subsequent quarter following the 12- month
anniversary for the following 12 quarters. The options will have a
strike price of GBP5.26, the mid-market closing price on AIM on
January 5, 2021.
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them
1. Details of the person discharging managerial responsibilities
(PDMR) / person closely associated
a) Name Craig Tooman
--------------------------- ------------------------------------------------
2. Reason for the notification
-----------------------------------------------------------------------------
a) Position / status Chief Financial Officer
--------------------------- ------------------------------------------------
b) Initial notification Initial notification
/ Amendment
--------------------------- ------------------------------------------------
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-----------------------------------------------------------------------------
a) Name Silence Therapeutics plc
--------------------------- ------------------------------------------------
b) LEI 213800SSURRJBX85SQ91
--------------------------- ------------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
-----------------------------------------------------------------------------
a) Description of Ordinary Shares in Silence Therapeutics
the financial instrument, plc
type of instrument
Identification
code ISIN for Silence Therapeutics plc Ordinary
Shares:
GB00B9GTXM62
--------------------------- ------------------------------------------------
b) Nature of the transaction Grant of Options under the Silence Therapeutics
plc 2018 Employee LTIP Scheme
--------------------------- ------------------------------------------------
c) Prices(a) and volume(s) 580,000 options with strike price of GBP5.26
--------------------------- ------------------------------------------------
d) Aggregated information
- Aggregated volume 580,000
- Price GBP5.26
--------------------------- ------------------------------------------------
e) Date of the transaction 6 January 2021
--------------------------- ------------------------------------------------
f) Place of the transaction Outside a trading venue
--------------------------- ------------------------------------------------
Enquiries:
Silence Therapeutics plc Tel: +1 (646) 637-3208
Gem Hopkins, Head of IR and Corporate Communications
ir@silence-therapeutics.com
Investec Bank plc (Nominated Adviser and Tel: +44 (0) 20
Broker) 7597 5970
Daniel Adams/Gary Clarence
European IR Tel: +44 (0) 20
Consilium Strategic Communications 3709 5700
Mary-Jane Elliott/ Angela Gray / Chris Welsh
silencetherapeutics@consilium-comms.com
U.S. IR Tel: +1 (443) 213-0505
Westwicke Partners
Peter Vozzo
peter.vozzo@westwicke.com
About Silence Therapeutics
Silence Therapeutics is developing a new generation of medicines
by harnessing the body's natural mechanism of RNA interference, or
RNAi, to inhibit the expression of specific target genes thought to
play a role in the pathology of diseases with significant unmet
medical need. Silence's proprietary technology can be used to
engineer short interfering ribonucleic acids (siRNAs) that bind
specifically to and silence, through the RNAi pathway, almost any
gene in the human genome to which siRNA can be delivered. Silence's
wholly owned product candidates include SLN360 designed to address
the high and prevalent unmet medical need in reducing
cardiovascular risk in people born with high levels of
Lipoprotein(a) and SLN124 to address beta-thalassemia and
myelodysplastic syndrome. Silence is also developing SLN500, a C3
targeting program, in partnership with Mallinckrodt Pharmaceuticals
to reduce the expression of the C3 protein for the treatment of
complement pathway-mediated diseases. Silence maintains ongoing
research and collaborations with AstraZeneca, Mallinckrodt
Pharmaceuticals and Takeda. For more information, please visit:
https://www.silence-therapeutics.com/
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHBBGDBUGGDGBL
(END) Dow Jones Newswires
January 06, 2021 06:08 ET (11:08 GMT)
Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From Apr 2024 to May 2024
Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From May 2023 to May 2024